An investor holds a portfolio consisting of high-yield corporate bonds issued by a single biotechnology firm facing upcoming regulatory approval hurdles, along with long-term zero-coupon U.S. Treasury bonds. Which of the following statements regarding the non-systematic and credit risks of these securities are correct?
- The corporate bonds carry business risk and credit risk that can be significantly reduced through asset diversification across different issuers and industries.Answer
- The long-term U.S. Treasury zero-coupon bonds carry negligible credit risk, yet remain subject to significant interest rate risk.Answer
- CSpreading the portfolio across bonds of ten different biotechnology companies will completely eliminate overall market risk.
- DThe primary risk impacting the long-term U.S. Treasury zero-coupon bonds is credit risk driven by potential corporate financial distress.
Answer
The correct statements are that the corporate bonds carry business and credit risks that can be mitigated through asset diversification, and that long-term U.S. Treasury zero-coupon bonds carry minimal credit risk while remaining exposed to interest rate risk.
Non-systematic risks such as business risk and credit (default) risk are specific to individual corporate issuers, like a biotech firm, and can be mitigated through asset diversification across multiple sectors. In contrast, U.S. Treasury obligations are backed by the U.S. government and carry minimal credit risk; however, long-duration zero-coupon Treasuries are heavily exposed to interest rate risk, which is a systematic risk.
Step-by-Step Solution
Key Concept
Non-Systematic Risk vs. Credit Risk and Diversification
Estimated Time:1m 30s